



ARECOR TO PRESENT AT BIO-EUROPE DIGITAL

Cambridge, UK., 26 October 2020: Arecor Limited ("Arecor" or "the Company"), the biopharmaceutical company advancing today's therapies to enable healthier lives, today announces Dr Sarah Howell, Chief Executive Officer, will present at BIO-EUROPE Digital, 26-29 October 2020.

Dr Howell will present Arestat™ formulation technology platform that improves patient outcomes of complex biopharmaceuticals across a broad range of therapeutic areas. Arecor is a clinical stage biotech company developing products in Diabetes and Anti-infectives. Dr Howell will share the data from the completed Phase I study of AT247, the Ideal Pump Insulin, in type 1 Diabetes. She will also discuss Arecor's novel formulations that enable innovative ready to use (liquid concentrate in a vial) and ready to administer (stable dilute solution in IV bag) products in anti-infectives.

Presenting Author:	Dr Sarah Howell
Session:	Drug Delivery
Available on:	Company Presentations on Demand

Bio-Europe

BIO-Europe is Europe's largest partnering conference serving the global biotechnology industry. Delegates from all parts of the biotechnology value chain come to BIO-Europe to quickly identify, engage and enter into strategic relationships that drive their businesses successfully forward. Investment and collaboration opportunities developed in prior BIO-Europe conferences have produced many highly successful business partnerships.

-ENDS-

For more information, please contact:

Arecor Limited

Dr Sarah Howell, Chief Executive Officer

www.arecor.com

Tel: +44 (0) 1223 426060

Email: info@arecor.com

Susan Lowther, Chief Financial Officer

Tel: +44 (0) 1223 426060

Email: info@arecor.com

Mo PR Advisory

Mo Noonan

www.mopradovisory.com

Mob: +44 (0) 7876 444977

Email: mo@mopradovisory.com

Notes to Editors

About Arecor



Arecor Limited is a biopharmaceutical company transforming patient care by bringing innovative medicines to market. Through the enhancement of existing medicines using our Arestat™ technology, we are developing a broad portfolio of therapies as part of our proprietary pipeline and through partnerships with leading pharmaceutical and biotech companies. Our treatments for people living with chronic disease are designed to simplify patient care and improve medication adherence.

For further details please see our website, www.arecor.com